Cracking the mysteries of Alzheimer’s disease
With Pfizer shutting down its neuroscience unit and a long list of failed late-stage trials, the sheer difficulty of improving the treatment of Alzheimer’s disease has become painfully clear. How can researchers crack the mystery of this much-feared neurodegenerative disease?